TISIDB

Summary
Symbol	SSTR5
Name	somatostatin receptor 5
Aliases	SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane; Multi-pass membrane protein.
Domain	PF00001 7 transmembrane receptor (rhodopsin family)
Function	Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerization.

> Gene Ontology [ TOP ]
Biological Process	GO:0000910 cytokinesis GO:0002790 peptide secretion GO:0002791 regulation of peptide secretion GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0009306 protein secretion GO:0009755 hormone-mediated signaling pathway GO:0009914 hormone transport GO:0010817 regulation of hormone levels GO:0015833 peptide transport GO:0023061 signal release GO:0030072 peptide hormone secretion GO:0030073 insulin secretion GO:0031960 response to corticosteroid GO:0032465 regulation of cytokinesis GO:0032467 positive regulation of cytokinesis GO:0033500 carbohydrate homeostasis GO:0038169 somatostatin receptor signaling pathway GO:0038170 somatostatin signaling pathway GO:0042593 glucose homeostasis GO:0042886 amide transport GO:0045787 positive regulation of cell cycle GO:0046879 hormone secretion GO:0046883 regulation of hormone secretion GO:0048545 response to steroid hormone GO:0050708 regulation of protein secretion GO:0050796 regulation of insulin secretion GO:0051302 regulation of cell division GO:0051384 response to glucocorticoid GO:0051781 positive regulation of cell division GO:0071383 cellular response to steroid hormone stimulus GO:0071384 cellular response to corticosteroid stimulus GO:0071385 cellular response to glucocorticoid stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:0090068 positive regulation of cell cycle process GO:0090087 regulation of peptide transport GO:0090276 regulation of peptide hormone secretion
Molecular Function	GO:0001653 peptide receptor activity GO:0004994 somatostatin receptor activity GO:0008188 neuropeptide receptor activity GO:0008528 G-protein coupled peptide receptor activity GO:0033218 amide binding GO:0042277 peptide binding GO:0042923 neuropeptide binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04024 cAMP signaling pathway hsa04080 Neuroactive ligand-receptor interaction
Reactome	R-HSA-373076: Class A/1 (Rhodopsin-like receptors) R-HSA-418594: G alpha (i) signalling events R-HSA-388396: GPCR downstream signaling R-HSA-500792: GPCR ligand binding R-HSA-375276: Peptide ligand-binding receptors R-HSA-162582: Signal Transduction R-HSA-372790: Signaling by GPCR

Summary
Symbol	SSTR5
Name	somatostatin receptor 5
Aliases	SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SSTR5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SSTR5
Name	somatostatin receptor 5
Aliases	SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SSTR5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SSTR5
Name	somatostatin receptor 5
Aliases	SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SSTR5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.998	0.341
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.151	0.432
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	3.7	0.0265
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.125	0.772
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.125	0.847
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.791	0.0264

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SSTR5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SSTR5
Name	somatostatin receptor 5
Aliases	SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SSTR5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SSTR5
Name	somatostatin receptor 5
Aliases	SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SSTR5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SSTR5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SSTR5
Name	somatostatin receptor 5
Aliases	SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SSTR5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SSTR5
Name	somatostatin receptor 5
Aliases	SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SSTR5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SSTR5
Name	somatostatin receptor 5
Aliases	SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SSTR5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SSTR5
Name	somatostatin receptor 5
Aliases	SS-5-R; somatostatin receptor subtype 5; SS5R; SS5-R; Somatostatin receptor type 5
Chromosomal Location	16p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SSTR5 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting SSTR5.

ID	Name	Drug Type	Targets	#Targets
DB00104	Octreotide	Small Molecule	SSTR1, SSTR2, SSTR5	3
DB04894	Vapreotide	Small Molecule	SSTR2, SSTR5, TACR1	3
DB06663	Pasireotide	Small Molecule	SSTR1, SSTR2, SSTR3, SSTR5	4
DB06791	Lanreotide	Small Molecule	SSTR2, SSTR5	2
DB13985	Lutetium Lu 177 dotatate	Small Molecule	SSTR1, SSTR2, SSTR3, SSTR4, SSTR5	5

Browse SSTR5